The interaction between conserved viral late domains and the cellular ESCRT proteins (NEDD4, TSG101 and Alix) represents a crucial step in the replication/egress of several viruses, making these PPIs promising but underexplored targets for the development of novel Broad-Spectrum Antivirals (BSAs). We report herein our ongoing efforts to obtain TSG101-targeting antivirals, offering a promising opportunity to identify broad-spectrum agents that are less susceptible to resistance development.
Targeting the ESCRT machinery: a promising strategy for the development of novel Broad-Spectrum Antivirals (BSAs) / Rubini, D., Martina, M.G., Valenti, M.E., Rodríguez-Martínez, A., Pérez-Sánchez, H., Harty, R.N., Parra-López, M., Diederich, S., Luque, I., Radi, M.. - (2024). (Drug Discovery Chemistry Europe, 2024 Barcellona 03/12 - 05/12/2024).
Targeting the ESCRT machinery: a promising strategy for the development of novel Broad-Spectrum Antivirals (BSAs).
Daniele RubiniConceptualization
;Maria Grazia Martina;Martina Eleonora Valenti;Marco Radi
2024-01-01
Abstract
The interaction between conserved viral late domains and the cellular ESCRT proteins (NEDD4, TSG101 and Alix) represents a crucial step in the replication/egress of several viruses, making these PPIs promising but underexplored targets for the development of novel Broad-Spectrum Antivirals (BSAs). We report herein our ongoing efforts to obtain TSG101-targeting antivirals, offering a promising opportunity to identify broad-spectrum agents that are less susceptible to resistance development.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
